Editorial: Canine melanoma in comparative oncology: Translate research advances to develop new diagnostic and therapeutic options.

Competing Interests: PB receives minority royalty payments from BI Animal Health for the Oncept melanoma vaccine as he is on the xenogeneic DNA patent with co-investigators at MSKCC. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.